Rachel Sanborn, M.D.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    AstraZeneca
    Topic:
    Advisory board, steering committee, educational moderator, funding for investigator-sponsored trial
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    EMD Serono
    Topic:
    Advisory board
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Daiichi Sankyo
    Topic:
    Advisory board
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Lilly Oncology
    Topic:
    Advisory board
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen Oncology
    Topic:
    Advisory board, steering committee
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Macrogenics
    Topic:
    Advisory board
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Sanofi Aventis
    Topic:
    Advisory board
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Regeneron
    Topic:
    Advisory board
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Mirati Therapeutics
    Topic:
    Advisory board
    Date added:
    09/26/2022
    Date updated:
    04/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    GlaxoSmithKline
    Topic:
    Advisory board
    Date added:
    09/26/2022
    Date updated:
    04/29/2024

Pages

Return to 2022 Seattle Multidisciplinary Thoracic Oncology Conference